RxDoctor Payments Data

Arnold Good, MD

Cardiovascular Disease · Gahanna, OHNPI 1336180835

Payments from drug & device makers

$762in general payments, 2019–2025

Across 26 payments — averaging $29.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$229
  • Medtronic$161
  • Boston Scientific$142
  • Novartis$120
  • Cardiovascular Systems Inc.$40
  • Biosense Webster, Inc.$17
  • plus $54 from 4 others

What the payments were for

  • Food & beverage$762100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$762 in reported general payments places this provider in the 35th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$79,063
Medicare patients
531
Services billed
1,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban343$310,951
JardianceEmpagliflozin100$72,895
EntrestoSacubitril/Valsartan59$60,469
XareltoRivaroxaban53$41,459
Repatha SureclickEvolocumab20$21,957
FarxigaDapagliflozin Propanediol17$17,196
Metoprolol Succinate613$5,809
Atorvastatin Calcium367$3,156
PradaxaDabigatran Etexilate Mesylate11$3,117
Ezetimibe147$2,448
Diltiazem 24hr Er (Cd)Diltiazem Hcl69$2,002
Ranolazine ErRanolazine20$1,391
Carvedilol164$1,152
Losartan Potassium119$1,032
Isosorbide Mononitrate ErIsosorbide Mononitrate89$1,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$120$60,46959 claims
Johnson & JohnsonXarelto$13$41,45953 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Gahanna

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →